TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors

S. E. Kaba, A. P. Kyritsis, K. Hess, W. K. Yung, R. Mercier, S. Dakhil, Kurt Jaeckle, V. A. Levin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. Patients and Methods: One hundred fifteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surgery and/or radiation therapy were enrolled onto a multicenter prospective study between 1989 and 1995. Patients received TPDC-FuHu in a repeated cycle every 6 weeks until recurrence or until they completed six courses. Results: Ninety-seven patients were assessable at the end of the study. Forty-eight had lung cancer (39 non-small-cell [NSCLC] and nine small- cell [SCLC]), 28 had breast cancer, nine had melanoma, and 12 had adenocarcinoma of different origins (three colon, two kidney, one bladder, one stomach, and five of unknown origin). The response and stable disease (SD) rate (overall response rate) was 52%, 66%, 60%, and 22% in patients with NSCLC, SCLC, breast cancer, and melanoma, respectively. Median time to progression (MTP) was 12, 26, 12, and 6 weeks, respectively, for the four groups. Side effects were mild to moderate in the majority of patients. Severe myelosuppression (grade 4) occurred in only 11% of the patients. Conclusion: TPDC-FuHu chemotherapy is an active treatment against recurrent brain metastases from breast cancer and SCLC, and to a lesser extent from NSCLC. This regimen is well tolerated and has acceptable toxicity.

Original languageEnglish (US)
Pages (from-to)1063-1070
Number of pages8
JournalJournal of Clinical Oncology
Volume15
Issue number3
DOIs
StatePublished - Jan 1 1997

Fingerprint

Mitolactol
Lomustine
Procarbazine
Thioguanine
Hydroxyurea
Brain Neoplasms
Fluorouracil
Drug Therapy
Breast Neoplasms
Therapeutics
Melanoma
Non-Small Cell Lung Carcinoma
Multicenter Studies
Stomach
Colon
Urinary Bladder
Adenocarcinoma
Radiotherapy
Prospective Studies
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kaba, S. E., Kyritsis, A. P., Hess, K., Yung, W. K., Mercier, R., Dakhil, S., ... Levin, V. A. (1997). TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. Journal of Clinical Oncology, 15(3), 1063-1070. https://doi.org/10.1200/JCO.1997.15.3.1063
Kaba, S. E. ; Kyritsis, A. P. ; Hess, K. ; Yung, W. K. ; Mercier, R. ; Dakhil, S. ; Jaeckle, Kurt ; Levin, V. A. / TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 3. pp. 1063-1070.
@article{ba140c63416f441188f43c351eb112ab,
title = "TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors",
abstract = "Purpose: To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. Patients and Methods: One hundred fifteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surgery and/or radiation therapy were enrolled onto a multicenter prospective study between 1989 and 1995. Patients received TPDC-FuHu in a repeated cycle every 6 weeks until recurrence or until they completed six courses. Results: Ninety-seven patients were assessable at the end of the study. Forty-eight had lung cancer (39 non-small-cell [NSCLC] and nine small- cell [SCLC]), 28 had breast cancer, nine had melanoma, and 12 had adenocarcinoma of different origins (three colon, two kidney, one bladder, one stomach, and five of unknown origin). The response and stable disease (SD) rate (overall response rate) was 52{\%}, 66{\%}, 60{\%}, and 22{\%} in patients with NSCLC, SCLC, breast cancer, and melanoma, respectively. Median time to progression (MTP) was 12, 26, 12, and 6 weeks, respectively, for the four groups. Side effects were mild to moderate in the majority of patients. Severe myelosuppression (grade 4) occurred in only 11{\%} of the patients. Conclusion: TPDC-FuHu chemotherapy is an active treatment against recurrent brain metastases from breast cancer and SCLC, and to a lesser extent from NSCLC. This regimen is well tolerated and has acceptable toxicity.",
author = "Kaba, {S. E.} and Kyritsis, {A. P.} and K. Hess and Yung, {W. K.} and R. Mercier and S. Dakhil and Kurt Jaeckle and Levin, {V. A.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1200/JCO.1997.15.3.1063",
language = "English (US)",
volume = "15",
pages = "1063--1070",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

Kaba, SE, Kyritsis, AP, Hess, K, Yung, WK, Mercier, R, Dakhil, S, Jaeckle, K & Levin, VA 1997, 'TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors', Journal of Clinical Oncology, vol. 15, no. 3, pp. 1063-1070. https://doi.org/10.1200/JCO.1997.15.3.1063

TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. / Kaba, S. E.; Kyritsis, A. P.; Hess, K.; Yung, W. K.; Mercier, R.; Dakhil, S.; Jaeckle, Kurt; Levin, V. A.

In: Journal of Clinical Oncology, Vol. 15, No. 3, 01.01.1997, p. 1063-1070.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors

AU - Kaba, S. E.

AU - Kyritsis, A. P.

AU - Hess, K.

AU - Yung, W. K.

AU - Mercier, R.

AU - Dakhil, S.

AU - Jaeckle, Kurt

AU - Levin, V. A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Purpose: To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. Patients and Methods: One hundred fifteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surgery and/or radiation therapy were enrolled onto a multicenter prospective study between 1989 and 1995. Patients received TPDC-FuHu in a repeated cycle every 6 weeks until recurrence or until they completed six courses. Results: Ninety-seven patients were assessable at the end of the study. Forty-eight had lung cancer (39 non-small-cell [NSCLC] and nine small- cell [SCLC]), 28 had breast cancer, nine had melanoma, and 12 had adenocarcinoma of different origins (three colon, two kidney, one bladder, one stomach, and five of unknown origin). The response and stable disease (SD) rate (overall response rate) was 52%, 66%, 60%, and 22% in patients with NSCLC, SCLC, breast cancer, and melanoma, respectively. Median time to progression (MTP) was 12, 26, 12, and 6 weeks, respectively, for the four groups. Side effects were mild to moderate in the majority of patients. Severe myelosuppression (grade 4) occurred in only 11% of the patients. Conclusion: TPDC-FuHu chemotherapy is an active treatment against recurrent brain metastases from breast cancer and SCLC, and to a lesser extent from NSCLC. This regimen is well tolerated and has acceptable toxicity.

AB - Purpose: To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. Patients and Methods: One hundred fifteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surgery and/or radiation therapy were enrolled onto a multicenter prospective study between 1989 and 1995. Patients received TPDC-FuHu in a repeated cycle every 6 weeks until recurrence or until they completed six courses. Results: Ninety-seven patients were assessable at the end of the study. Forty-eight had lung cancer (39 non-small-cell [NSCLC] and nine small- cell [SCLC]), 28 had breast cancer, nine had melanoma, and 12 had adenocarcinoma of different origins (three colon, two kidney, one bladder, one stomach, and five of unknown origin). The response and stable disease (SD) rate (overall response rate) was 52%, 66%, 60%, and 22% in patients with NSCLC, SCLC, breast cancer, and melanoma, respectively. Median time to progression (MTP) was 12, 26, 12, and 6 weeks, respectively, for the four groups. Side effects were mild to moderate in the majority of patients. Severe myelosuppression (grade 4) occurred in only 11% of the patients. Conclusion: TPDC-FuHu chemotherapy is an active treatment against recurrent brain metastases from breast cancer and SCLC, and to a lesser extent from NSCLC. This regimen is well tolerated and has acceptable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0031044739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044739&partnerID=8YFLogxK

U2 - 10.1200/JCO.1997.15.3.1063

DO - 10.1200/JCO.1997.15.3.1063

M3 - Article

C2 - 9060546

AN - SCOPUS:0031044739

VL - 15

SP - 1063

EP - 1070

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -

Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. Journal of Clinical Oncology. 1997 Jan 1;15(3):1063-1070. https://doi.org/10.1200/JCO.1997.15.3.1063